Belissa

Quick links to important sections

Belissa

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Belissa

Quick Facts

Property Description
Active Ingredients Chlormadinone acetate, Ethinyl Estradiol
Form Film-coated tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Contraceptive protection
Origin Synthetic hormones
Status Prescription-only medicine (POM)

What Type of Medicine is Belissa, and What is its Composition?

Belissa is a prescription-only medicine (POM) that functions as a combined oral contraceptive (COC), serving the general purpose of providing contraceptive protection against pregnancy. It is classified under the pharmacological class of hormonal contraceptives and contains a fixed combination of two distinct, synthetic hormones for systemic, oral administration. The active components are the progestin Chlormadinone acetate and the estrogen Ethinyl Estradiol, which is recognized as a synthetic steroid. The medication is presented as a monophasic preparation in the form of a film-coated tablet. The use of a combination of an estrogen and a progestin is a recognized method for the prevention of conception.

Understanding the General Purpose of Belissa

The central purpose of Belissa is to provide primary hormonal contraception for reproductive-aged women. However, the formulation's differentiation lies in the specific choice of progestin. The component Chlormadinone acetate possesses an antiandrogenic property. This feature means that, in addition to preventing the release of an egg, the medication has a secondary benefit relevant to hormone-related dermatological concerns. For a typical patient, this formulation offers a treatment option where contraceptive protection is desired alongside the potential for improvement in conditions like moderate acne vulgaris.

What side effects are possible with Belissa?

Possible side effects and safety information for Belissa

Official regulatory documents structure the safety profile of a medicine by categorizing adverse reactions based on severity, frequency, and the body system affected. This provides a clear, formalized summary of the risks identified during clinical trials and post-marketing surveillance.

Adverse Reactions Classified by Frequency

Adverse reactions are formally listed according to their incidence rate in clinical studies, following standardized classifications (e.g., Very Common, Common, Uncommon, Rare) defined by regulatory authorities like the EMA and FDA. This frequency-based classification allows for a precise understanding of the drug's overall side effect profile.

Serious Adverse Reactions

Regulatory documents highlight Serious Adverse Reactions, which are defined as events that are life-threatening, result in hospitalization, cause persistent or significant disability, or constitute a congenital anomaly. These events are subject to continuous, expedited reporting under official pharmacovigilance rules.

System-Organ Classes (SOCs)

Reported adverse reactions are grouped into System-Organ Classes (SOCs), such as 'Gastrointestinal disorders,' 'Nervous system disorders,' or 'Skin and subcutaneous tissue disorders.' This grouping organizes information by the body system impacted, aiding in the identification of potential organ-related risks.

Regulatory Safety Category Purpose in Official Documents
Frequency Classification Quantifies the rate of occurrence of adverse reactions.
System-Organ Classes Groups side effects by the bodily system they affect.
Serious Adverse Reactions Identifies the most clinically significant and high-risk events.
Post-Marketing Data Captures rare, late-onset, or previously unknown safety risks.

Context of Safety Monitoring

The safety profile is continually updated based on post-marketing surveillance, which ensures that rare adverse events and long-term effects not apparent in initial trials are detected and incorporated into the official labeling. The medicine's risk profile is thus a dynamic document, maintained under strict government regulatory oversight.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Belissa overdose is based on the general documented experience with combined oral contraceptives (COCs), specifying the clinical presentation and required emergency actions.

Documented Overdose Presentations Overdose manifestations are typically non-severe. Symptoms listed in regulatory documentation for high-dose exposure include nausea and vomiting. Other documented effects may include breast tenderness, headache, and drowsiness. A predictable effect post-overdose is withdrawal bleeding (vaginal bleeding), which is often delayed by two to seven days. The acute risk is classified as having low toxicity and is not likely to be life-threatening.

Required Emergency Actions Regulatory guidance explicitly mandates that individuals must seek immediate medical attention following an overdose. The recommended procedure includes contacting a Poison Control Center or calling emergency services if collapse or difficulty breathing occurs. No specific antidotes are known for this overdose.

Management and Monitoring Management procedures described in official documentation are symptomatic and supportive. This includes the potential use of activated charcoal in extreme cases and monitoring of vital signs during observation. This overdose information is relevant to the population for whom the medicine is indicated: patients after menarche.

Therapeutic Uses of Belissa

What Belissa Treats: Main Uses and Benefits

Belissa is primarily used to provide effective contraceptive protection for reproductive-aged women, which is its core therapeutic purpose. It is relevant in clinical settings where patients require a systemic, long-term method for fertility management, and it supports planning related to fertility management. Hormonal contraceptives are often used to help address menstrual-related disorders such as pain and irregular bleeding, in addition to their contraceptive efficacy.

Beyond contraception, Belissa is relevant for easing symptoms related to androgen activity, including moderate acne vulgaris, excessive skin oiliness (seborrhea), and unwanted hair growth (hirsutism). The medication offers supportive benefit in managing recurrent symptoms tied to the menstrual cycle, including easing the intense cramping pain of primary dysmenorrhea and supporting the establishment of a more predictable cycle pattern. This use is relevant when symptomatic relief is needed and contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Relief for Key Symptom Domains
May assist in easing the overall symptom load of moderate acne vulgaris and seborrhea.
May assist with easing symptoms of intense cramping pain associated with primary dysmenorrhea.
Is commonly used to help with effective contraceptive protection against unintended pregnancy.

Regulatory References

  1. National Institutes of Health (NIH) literature on combined oral contraceptives

Eligibility and Restrictions for Use

Belissa is indicated for use by females of reproductive potential and is not indicated for use in post-menopausal women. Eligibility for this medicine is strictly defined by an absolute list of regulatory contraindications that primarily focus on minimizing the risk of serious thrombotic events.

Contraindicated Populations

Use of Belissa is prohibited for any female with a high risk of arterial or venous thrombotic diseases, including a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), stroke, or Myocardial Infarction (MI). Use is also contraindicated in females over 35 years of age who smoke ge 15 cigarettes/day, and in those with migraine with focal neurological symptoms (aura), regardless of age.

Additionally, Belissa is contraindicated in patients with current or history of breast cancer, liver tumors or severe hepatic disease, and for those with undiagnosed abnormal uterine bleeding. The medicine must be stopped at least four weeks before and two weeks after any major surgery involving prolonged immobilization. Belissa is contraindicated in known or suspected pregnancy.

What should I know about interactions with other medicines?

Use of this combined hormonal contraceptive is contraindicated with specific combination drug regimens used to treat Hepatitis C Virus (HCV). These include medicinal products containing ombitasvir/paritaprevir/ritonavir (pm dasabuvir), glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. This formal restriction is based on the documented risk of elevated liver transaminases. The contraceptive can be restarted two weeks following completion of the HCV treatment regimen.

Co-administration with substances that are strong or moderate enzyme inducers (e.g., certain anticonvulsant medicines or the herbal product St. John’s Wort) may cause a pharmacokinetic interaction that reduces contraceptive effectiveness and increases breakthrough bleeding. Conversely, co-administration with CYP3A4 inhibitors (e.g., certain antifungal medicines) may increase the plasma concentrations of the contraceptive hormones, which is associated with a potential increase in the risk of thrombosis.

This medication also affects the exposure of co-administered drugs. It reduces the plasma concentration of Lamotrigine through the induction of metabolism. Additionally, the estrogen component may raise the serum concentration of binding globulins (e.g., Thyroxine-Binding Globulin), which requires consideration when adjusting the dosage of co-administered thyroid or cortisol replacement therapy.

Mechanism of Action

Belimumab is a human monoclonal IgG1lambda antibody that functions as a selective inhibitor of the soluble B-lymphocyte stimulator protein, known as BLyS (also referred to as BAFF). The drug circulates systemically and binds to BLyS with high affinity, preventing its interaction with receptors on the B-cell surface, specifically the B-cell activating factor receptor (BAFF-R), TACI, and BCMA. This competitive antagonism reduces the circulating, biologically active concentration of BLyS. Since BLyS is a requisite cytokine for B-cell survival, the resulting lack of BLyS-mediated prosurvival signaling promotes the selective induction of apoptosis in autoreactive B-lymphocytes. This intracellular cascade leads to a reduction in the number of B-cell populations, including naive B cells and activated B cells, and consequently decreases the downstream production of autoantibodies by plasma cells. The systemic physiological consequence is a quantitative modulation of the humoral immune response.

Dosage and Administration Information

How to use Belissa

Belissa (Chlormadinone acetate and Ethinyl Estradiol) is a combined hormonal contraceptive administered through the oral route. The medicine is presented as a monophasic film-coated tablet and is taken once daily in a precisely structured, continuous cyclic pattern.


Official Administration Schedule

The entire course of use is defined by a repetitive 28-day cycle. The standard dosage involves taking one tablet per day at the same time every day to maintain consistent hormone exposure. The specific schedule follows one of two common regimens, consisting of a fixed number of active tablets followed immediately by a hormone-free interval.

Cycle Regimen Active Tablets Hormone-Free Interval
Conventional 21 consecutive days 7 days (tablet-free)
Extended Active 24 consecutive days 4 days (hormone-free/placebo)

Procedural Instructions

Tablets must be taken in the sequence directed by the blister packaging, and the first day of the menstrual period is a common starting point for initiation (Day 1 Start). Procedurally, if vomiting or severe diarrhea occurs within 3 to 4 hours of intake, the active tablet is treated as a missed dose. In such cases, and for any other missed active dose, it is standard procedure to follow specific instructions provided in the product labeling to determine the need for additional non-hormonal contraception. The medication is generally swallowed whole with water, and some labels suggest taking the dose after food for improved tolerance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Belissa


Evidence for Use in Contraceptive Protection

The core research for this medication was studied for its primary use in preventing pregnancy. The evidence is derived from large-scale, prospective, non-interventional observational studies and dedicated non-randomized clinical trials. Research examined how reliably the medication prevents unintended pregnancy, which was measured by a calculation known as the Pearl Index. Studies reported measurements of the Pearl Index, which is a metric examined in the combined oral contraceptive class. Research describes patterns where cycle control metrics were observed during the study period, often by the sixth cycle of observation. Most primary regulatory studies emphasize short-term to intermediate-term follow-up (typically 6 to 12 cycles).


Evidence for Use in Moderate Acne Vulgaris

Research examined the medication for its application in women with moderate acne in randomized, double-blind, placebo-controlled Phase III clinical trials. These studies focused on women with clinically diagnosed mild to moderate papulopustular acne. This research explored outcomes linked to inflammatory or irritative states of the skin, measuring changes in the number of inflammatory and non-inflammatory lesions. The findings describe patterns observed in the studies, where changes in the number of inflammatory lesions were monitored between the study drug group and the placebo group after six cycles of use. The main uncertainty relates to the duration of follow-up; the primary endpoint for acne improvement was assessed after six medication cycles, and there is limited information for long-term outcomes.


What Is Still Uncertain about the Evidence Base

Evidence quality varies across studies for the medication’s application in secondary areas like primary dysmenorrhea (painful periods), seborrhea (excessive skin oiliness), and hirsutism (unwanted hair growth). Findings for these indications often derive from large observational settings, with limited dedicated, placebo-controlled trials. Comparative evidence is lacking for how this specific formulation performs against all other available anti-androgenic combined hormonal contraceptives for acne and related skin disorders. Certainty remains low to moderate for the long-term effects of using the medication solely for the management of these secondary androgen-related conditions.

Frequently Asked Questions (FAQ)

Common questions about Belissa (FAQ)

Q: How quickly does Belissa start to work?

Official product information indicates that combined hormonal contraceptives are highly effective when taken as directed. However, for maximum contraceptive protection, product labeling typically suggests using an additional non-hormonal method during the first 7 to 9 days of the initial cycle.

Q: How long do the effects of Belissa last?

The formulation is designed for once-daily dosing to maintain consistent hormone exposure over a 24-hour period. Studies examining the pharmacokinetics show that the active progestin component has a terminal half-life of approximately 34 to 39 hours once consistent levels are reached.

Q: Can Belissa be taken with common pain relievers like ibuprofen?

Official interaction warnings advise caution when taking combined hormonal contraceptives with nonsteroidal anti-inflammatory drugs (NSAIDs), which includes common pain relievers like ibuprofen. This is due to a documented, albeit low, risk of elevated potassium levels, especially in patients with pre-existing conditions.

Q: Does Belissa cause weight gain or weight loss?

According to official regulatory documents, an increase in body weight is listed as a common side effect of the medicine or its class, meaning it has been reported to occur in 1% to 10% of users in clinical studies.

Q: Is it normal to feel tired after starting Belissa?

Yes, official safety information indicates that fatigue or a general feeling of malaise is classified as a common side effect. This means it has been reported in clinical data to affect between 1% and 10% of users.

Q: Does Belissa affect sleep patterns?

Insomnia, or difficulty sleeping, is listed in regulatory documents as an uncommon side effect associated with the use of the medicine. This means it was reported in 0.1% to 1% of users during clinical studies.

Q: Is Belissa safe to use if I have diabetes?

Combined hormonal contraceptives can decrease insulin sensitivity, which is relevant for patients with diabetes. Therefore, women with prediabetes or diabetes may require close monitoring of their glucose levels when using this medication. The medicine is formally contraindicated for women with uncontrolled diabetes or those with vascular complications.

Q: Does Belissa interact with alcohol?

Regulatory warnings note that heavy, long-term alcohol consumption may increase the risk of adverse cardiovascular events associated with hormonal contraceptives. Alcohol may also compromise contraceptive protection if vomiting occurs shortly after taking a tablet.

Q: Can Belissa affect my ability to drive or operate machinery?

Official product documents do not contain a direct warning against driving or operating machinery. However, patients should be mindful that side effects such as headaches, dizziness, or rare visual disturbances may occur, which could affect concentration or reaction time.

Q: Can Belissa be taken if I have kidney problems?

Official warnings indicate that kidney disease is a pre-existing condition that may require special caution or monitoring when using this medication. In particular, severe or complicated kidney issues may be linked to contraindications, especially if associated with uncontrolled high blood pressure.

Q: Is there an established link between Belissa and mood changes?

Yes, regulatory documents list mood disorder, affect disorder, and anxiety as common psychiatric side effects that have been reported by users. This suggests an established link between the medication and the potential for mood changes.

Q: Can Belissa affect my vision?

Vision changes or sudden, unexplained loss of vision are listed in official warnings as symptoms that could signal a serious adverse reaction, such as a thrombotic event (blood clot), and indicate the need for immediate medical evaluation.

Q: Is it common for Belissa to cause temporary headaches?

Yes, regulatory safety information classifies headache as a very common side effect of the medicine or its class, meaning it was reported in over 10% of users. Migraine is also listed as a common side effect.

Q: Is Belissa a steroid?

The medicine is classified as a Combined Hormonal Contraceptive. However, its active components are synthetic hormones; official documents indicate that the estrogen ingredient, ethinyl estradiol, is chemically recognized as a synthetic steroid.

Q: What is the biggest difference between Belissa and [Similar Drug Name]?

The formulation is differentiated by its specific progestin component, Chlormadinone acetate. This progestin possesses antiandrogenic properties, meaning it helps to counteract effects caused by androgens. This property provides the secondary benefit of managing conditions like moderate acne vulgaris.

Q: What are the most common side effects people report with Belissa?

Official regulatory documents classify side effects based on how frequently they are reported in clinical studies. The most common side effects for this class of medicine typically include headache, nausea, breast pain or tenderness, and bleeding or spotting between periods.

Q: Is Belissa safe for people with high blood pressure?

Combined hormonal contraceptives are formally contraindicated (prohibited) for women with uncontrolled high blood pressure or those with hypertension complicated by vascular disease. For individuals with well-controlled high blood pressure, close blood pressure monitoring may be necessary.

Q: Why do some people experience mild stomach upset when taking Belissa?

Gastrointestinal issues, such as nausea, vomiting, and abdominal pain, are listed in regulatory safety summaries as common side effects of the medicine. The administration instructions sometimes suggest taking the dose after food to help improve digestive tolerance.

Q: How does Belissa compare to natural or herbal remedies?

Official warnings advise that the medication can interact with herbal supplements that act as enzyme inducers, most notably St. John's Wort. These interactions can significantly reduce the concentration of the contraceptive hormones in the body, potentially lowering its effectiveness.

Q: Are there any specific food interactions to know about when using Belissa?

No specific dietary changes are generally required. However, the estrogen component can interact moderately with some substances, such as caffeine, by potentially increasing its levels in the body. Taking the medicine after a meal is an administration tip sometimes used to help improve tolerance.

Q: What does 'contraindication' mean regarding Belissa?

A contraindication is an absolute, formal restriction against using the medicine. For Belissa, these restrictions are based on pre-existing conditions that are documented to place a patient at an unacceptably high risk for serious adverse events, such as life-threatening blood clots.

Q: Is Belissa considered a long-term treatment option?

Yes, combined hormonal contraceptives are generally used long-term for contraception and the management of associated conditions in reproductive-aged women. However, due to the recognized long-term risks, periodic assessment of the individual's safety profile by a healthcare professional is recommended.

Q: What should I do if a rare side effect is experienced while on Belissa?

If serious or concerning symptoms occur, immediate medical evaluation is necessary. Furthermore, regulatory documents guide the reporting of suspected adverse reactions to a healthcare provider or through the national regulatory reporting system for continuous safety monitoring.

Q: Are there any warnings about using Belissa with supplements?

Official warnings focus primarily on herbal supplements classified as enzyme inducers, like St. John’s Wort, because they can reduce the drug's effectiveness. Caution is generally required for all co-administered supplements, as they can potentially alter the concentration of the contraceptive hormones.

Q: Will Belissa interact with my antidepressant medication?

Regulatory warnings exist for a range of medications, including some in the antidepressant class, that are known as strong or moderate enzyme inducers or inhibitors. These types of interactions can either reduce the contraceptive’s effectiveness or cause an increase in the hormone levels in the body.

Q: What is the meaning of the warning about 'drug-drug interactions' for Belissa?

A warning about drug-drug interactions means that when Belissa is taken alongside another medication, the way the body processes one or both drugs may change. This could lead to a reduction in the contraceptive's efficacy or increase the risk of serious side effects, such as blood clots.

Q: Are there specific symptoms that require immediate medical attention while using Belissa?

Yes, official warnings define specific symptoms that indicate a potentially serious adverse reaction requiring immediate medical attention. These include sudden, severe headaches, chest pain, difficulty breathing, slurred speech, vision changes, or unexplained swelling and pain in the legs.

Q: What is the typical timeframe for seeing the full benefit of Belissa?

While contraceptive protection is effective soon after starting, the full therapeutic benefit for the secondary uses, such as improvement in moderate acne, is typically not assessed until after several full cycles of continuous use. Clinical studies for acne improvement generally measured results after six cycles of medication use.

Q: Is Belissa okay to use while breastfeeding?

Combined hormonal contraceptives containing Ethinyl Estradiol may suppress the production and decrease the quality of breast milk. Due to this risk, the medicine is generally not recommended during the initial six weeks after childbirth and should only be used after a careful consultation with a healthcare provider.

Q: Has Belissa been studied in children or teenagers?

The medicine is indicated for use in females of reproductive potential who have already started their menstrual period (menarche). Clinical trials for the secondary indication of moderate acne included women aged 14 years and older who met the criteria for menarche.

Q: Do I need to change my diet while taking Belissa?

No major, restrictive dietary changes are typically required when using this medicine. However, if a patient has pre-existing conditions like diabetes, specialized diet and monitoring may be necessary. General caution is noted regarding high intake of caffeine, as hormone levels can affect its metabolism.

Q: Does Belissa require any special monitoring or blood tests?

Yes, official guidelines advise that periodic monitoring may be required. This includes regular monitoring of blood pressure, especially for individuals with existing hypertension. Additionally, women who are prediabetic or diabetic require periodic blood glucose monitoring.

Q: Are there different strengths of Belissa available?

Belissa is manufactured as a specific monophasic tablet containing a fixed dose of the two active ingredients. While the class of combined hormonal contraceptives offers formulations with varying estrogen strengths (categorized as high, moderate, or low dose), Belissa itself is a fixed-strength product.

How should Belissa be stored and disposed of?

The official regulatory requirements dictate specific conditions for storing and disposing of Belissa (chlormadinone acetate/ethinyl estradiol) tablets to maintain product quality and ensure environmental safety. The medication must be stored in a cool, dry place at room temperature, generally meaning it must be kept below 30°C. It is required to be kept in its original blister pack and outer carton to protect the hormonal components from light and moisture.

Storage and Disposal Requirements

Classification Official Regulatory Requirement
Storage Temperature Store at room temperature, below 30°C.
Protection Must be protected from light and stored in a dry place.
Child Safety Store strictly out of the sight and reach of children.
Disposal Rule Do not dispose of unused medicine in household trash or wastewater.

Disposal must comply with local regulations; unused tablets should be returned to a pharmacy or designated collection program as directed by government guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Belissa found in:

A-Z Index: